Skip to main content
Terug
CRON logo

Cronos Group Inc.

Datakwaliteit: 100%
CRON
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
€ 2,52
▲ € 0,13 (5,44%)
Marktkapitalisatie: 969,24M
Dagbereik
€ 2,40 € 2,53
52-Weeksbereik
€ 1,60 € 3,43
Volume
1.012.570
50D / 200D Gem.
€ 2,61 / € 2,46
Vorige Slotkoers
€ 2,39

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -102,6 0,4
P/B 0,9 2,9
ROE % -0,9 3,7
Net Margin % -4,9 3,8
Rev Growth 5Y % 31,6 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 31,55% annually over 5 years — strong growth
Earnings declined -123,00% over the past year
Debt/Equity of 0,00 — conservative balance sheet
Generating 151.611,0 in free cash flow
PEG of 0,88 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 32,85%

Groei

Revenue Growth (5Y)
31,55%
Revenue (1Y)64,40%
Earnings (1Y)-123,00%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-0,88%
ROIC-0,20%
Net Margin-4,89%
Op. Margin-1,51%

Veiligheid

Debt / Equity
0,00
Current Ratio19,59
Interest Coverage0,00

Waardering

P/E Ratio
-102,60
P/B Ratio0,89
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 64,40% Revenue Growth (3Y) 48,88%
Earnings Growth (1Y) -123,00% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 31,55% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 193,36M Net Income (TTM) -9,45M
ROE -0,88% ROA -0,79%
Gross Margin 32,46% Operating Margin -1,51%
Net Margin -4,89% Free Cash Flow (TTM) 151.611,0
ROIC -0,20% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 19,59
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -102,60 P/B Ratio 0,89
P/S Ratio 5,01 PEG Ratio 0,88
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 969,24M Enterprise Value 178,95M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 193,36M 117,62M 87,24M 86,75M 64,56M
Net Income -9,45M 41,08M -73,96M -168,73M -396,11M
EPS (Diluted) -0,02 0,11 -0,19 -0,45 -1,07
Gross Profit 62,76M 25,20M 11,91M 15,44M -17,59M
Operating Income -2,93M -76,53M -84,80M -111,43M -291,97M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,20B 1,17B 1,14B 1,21B 1,40B
Total Liabilities 54,18M 55,33M 44,14M 72,05M 63,46M
Shareholders' Equity 1,09B 1,06B 1,10B 1,14B 1,34B
Total Debt 1,51M 2,02M 2,55M 3,88M 9,81M
Cash & Equivalents 791,79M 858,81M 669,29M 764,64M 886,97M
Current Assets 944,09M 936,11M 933,31M 960,16M 1,08B
Current Liabilities 48,19M 49,70M 41,40M 68,12M 54,37M

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#801 of 820
7
Custom Full Throttle
#14 of 146
69

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Full Throttle
Mar 24, 2026